Navigation Links
Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
Date:7/20/2011

RICHMOND, Calif., July 20, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its second quarter 2011 financial results on Wednesday, July 27, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 85799075.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on July 27, 2011 to midnight ET on August 3, 2011. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406 respectively. The conference ID number for the replay is 85799075.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/6/2019)... ... ... WCCT Global, Inc ., a full-service early phase contract research organization (CRO) ... 3 awards at the 2019 CRO Leadership Awards, to be held on June 24, ... Quality and Compatibility (Access to desired markets, cultural fit, timely project communications etc.) and ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object Pharma, ... the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the production ... and commercialization rights to a full spectrum of botulinum neurotoxins, as well as ...
(Date:5/15/2019)... ... May 15, 2019 , ... Milton Hershey School® has named William Charles Ballough ... the biomedical industry, where he is changing lives by creating solutions to global healthcare ... epitomizes the vision of our founders – Milton and Catherine Hershey – who always ...
(Date:5/8/2019)... ... , ... Standing at 16.2 hands, Atlas is on the large side for a Quarter Horse. ... racing, among other activities. When loping around a corner in late 2017, Atlas tripped ... horse to only being able to walk. Fortunately Atlas’ owner, Kelly, sought the opinion ...
Breaking Biology Technology:
(Date:6/11/2019)... ... June 12, 2019 , ... With a rapidly growing customer ... the Geneious Biologics platform as a premium hub for bioinformatics and computer programming ... “The Geneious team has done an excellent job accommodating our specific data, resulting ...
(Date:6/6/2019)... ... 2019 , ... Ziegler, a specialty investment bank, is pleased ... (PBM) on its recent acquisition by PathGroup. , Headquartered in Lewisville (Dallas), ... than one dozen hospitals and surgery centers in the Dallas-Fort Worth and broader ...
(Date:6/4/2019)... ... June 04, 2019 , ... Most ... features of seizure risk signals, usually based on variations of amplitude, frequency or ... only acceptable diagnostic methodology due to the complexity and variability of the signal, ...
Breaking Biology News(10 mins):